Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00123890 · ClinicalTrials.gov registry record · Phase 3
Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00123890: Clinical Trial Phase 3 study, sponsored by GlaxoSmithKline.
NCT00123890 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00123890, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.
Interventions
- DRUG GW873140
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-06 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Why NCT00123890 stopped before completion
NCT00123890 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which GW873140 is the first listed.
NCT00123890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00123890 about?
NCT00123890 is a clinical study titled "Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140". The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.
What is the current status of trial NCT00123890?
This trial is currently terminated. It is a Phase 3 study. The study started on 2005-06. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00123890?
The interventions under investigation include: GW873140 (DRUG).
Who is sponsoring clinical trial NCT00123890?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia